From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA questions Amgen drug for prostate cancer

from The Associated Press via Los Angeles Times

Scientists for the Food and Drug Administration say an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects. The FDA will ask a panel of experts whether the benefits of Xgeva outweigh its risks, which included bone disease in about 5 percent of patients. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063